53例非霍奇金淋巴瘤患者临床及实验资料分析

目的 分析多种因素对恶性淋巴瘤（ＭＬ）预后的影响，并探讨聚合酶链反应（ＰＣＲ）检测免疫球蛋白重链（ＩｇＨ）和Ｔ细胞受体（ＴＣＲ）基因重排在协助Ｔ、Ｂ分型的临床意义。方法 通过ＳＡＢＣ法进行免疫分型、ＰＣＲ方法检测ＩｇＨ（ＦＲ２Ａ，３Ａ）和ＴＣＲ（β，γ）基因重排。结果 非霍奇金淋巴瘤（ＮＨＬ）发病年龄分布呈递增趋势，危险比率每年剃守１．０３９＾ｎ；Ｂ－ＮＨＬ发病率为６６．７％，Ｔ－ＮＨＬ为３１．１

An analysis of the clinical and laboratory data of 53 cases of non-Hodgkin's lymphoma

OBJECTIVE: To analyse the influence of factors on the prognoses of non-Hodgkin's lymphoma (NHL) and the clinical usage of IgH and T cell receptor(TCR) gene rearrangement for NHL typing. METHODS: Immunological phenotyping was carried out by SABC, and IgH(FR2A, FR3A) and TCR(beta, gamma) detection by PCR. RESULTS: The age curve of NHL was increased parallel with the patient's age increasing, hazard ratio was increased 1.039n annually. The incidence of B cell NHL(B-NHL) was 66.7%, T cell NHL(T-NHL) was 31.1%, low grade NHL was 56%, middle and high grade NHL were 44%. The positivity of IgH and TCR gene rearrangement in NHL patients were 75% by PCR detection, T and B classification was same as phenotyping. The 3 and 5 years survival ratio: HD were 83.3% and 62.5%, stage I-II of NHL were 88.9% and 66.7%, stage III-IV of NHL were 39.9% and 33.3%, Low grade NHL were 65.1% and 48.8%, middle and high grade NHL were 47.6% and 39.6%. The survival time of APBSCT group was longer than that of the conventional therapy group. CONCLUSION: Age, T,B classification, grading and staging are the important factors which affect on NHL prognoses. APBCST can improve NHL prognoses, especially for those of stage III-IV patients. Molecular biological methods can help T/B classification when it couldn't be confirmed by phenotyping.